More Clinical Data Required To Support European Approval Of Desvenlafaxine As A Potential Treatment For Vasomotor Symptoms

Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that it would need to conduct additional clinical studies to address questions from the Committee for Medicinal Products for Human Use (CHMP) regarding the risk-benefit profile of desvenlafaxine as a treatment for vasomotor symptoms. As a result, Wyeth voluntarily withdrew its application for European Marketing Authorisation for desvenlafaxine for the treatment of vasomotor symptoms (hot flashes) associated with menopause.

More: continued here

Filed under: Endocrinology on March 15th, 2008